This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / BioAge Labs Class Action Lawsuit
Business class action

BioAge Labs Class Action Lawsuit

Analysis based on 10 articles · First reported Jan 07, 2025 · Last updated Jan 17, 2025

Sentiment
-70
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against BioAge Labs and the discontinuation of its STRIDES Phase 2 trial have caused a significant decline in BioAge Labs' stock price, impacting investors who purchased shares during its IPO. This event highlights the risks associated with clinical-stage biopharmaceutical companies and the importance of transparent communication regarding drug trials.

Biotechnology Pharmaceuticals Legal Services
Event Summary

BioAge Labs, a clinical-stage biopharmaceutical company, is facing a class action lawsuit filed by Bleichmar Fonti & Auld LLP. The lawsuit alleges that BioAge Labs made misleading statements in its IPO documents regarding its STRIDES Phase 2 trial for azelaprag, a drug candidate for obesity. The company had stated that Eli Lilly and Company was collaborating on the trial and anticipated positive topline results. However, BioAge Labs discontinued the trial on December 6, 2024, citing safety concerns after subjects exhibited elevated liver enzyme levels. This news led to a more than 76% drop in BioAge Labs' stock price. Investors have until March 10, 2025, to seek appointment as lead plaintiff in the case, which is pending in the United States — United States District Court for the Northern District of California.

Key Actions
100 Bleichmar Fonti & Auld LLP filed lawsuit BioAge Labs
95 BioAge Labs discontinued trial
Entities Involved
stock
Eli Lilly and Company
Eli Lilly and Company was collaborating with BioAge Labs on the STRIDES trial, advising and assisting on its design and execution, but is not directly implicated in the lawsuit.
Importance 20.0 Sentiment 0.0
priv
BioAge Labs
Importance 0.0 Sentiment 0.0
priv
Bleichmar Fonti & Auld LLP
Importance 0.0 Sentiment 0.0
stock
Tesla, Inc.
Importance 0.0 Sentiment 0.0
govactor
United States — United States District Court for the Northern District of California
Importance 0.0 Sentiment 0.0
stock
Sun Pharma
Importance 0.0 Sentiment 0.0
Relationships
Bleichmar Fonti & Auld LLP related ↔ United States — United States District Court for the Northern District of California
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.